Article Text

other Versions

Download PDFPDF
Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring
  1. Wei Zhao1,2,
  2. Emmanuel Lopez3,
  3. Valérie Biran4,
  4. Xavier Durrmeyer5,
  5. May Fakhoury1,
  6. Evelyne Jacqz-Aigrain1,2
  1. 1Department of Pediatric Pharmacology and Pharmacogenetics, Hôpital Robert Debré, Université Paris Diderot, Assistance Publique—Hôpitaux de Paris, Paris, France
  2. 2Clinical Investigation Center CIC9202, INSERM, Paris, France
  3. 3Department of Neonatology, Groupe Hospitalier Cochin-Broca-Hotel Dieu, Université Paris Descartes, Assistance Publique—Hôpitaux de Paris, Paris, France
  4. 4Department of Neonatology, Hôpital Robert Debré, Université Paris Diderot, Assistance Publique—Hôpitaux de Paris, Paris, France
  5. 5Department of Neonatology, Hôpital Intercommunal de Créteil, Université Paris-Est Créteil, Assistance Publique—Hôpitaux de Paris, Créteil, France
  1. Correspondence to Professor Evelyne Jacqz-Aigrain, Department of Pediatric Pharmacology and Pharmacogenetics, Clinical Investigation Center CIC9202 INSERM, Hôpital Robert Debré, 48 Boulevard Sérurier, 75935 Paris Cedex 19, France; evelyne.jacqz-aigrain{at}


Objective Because pharmacokinetic data are limited, continuous infusions of vancomycin in neonates are administered using different dosing regimens. The aim of this work was to evaluate the results of vancomycin therapeutic drug monitoring (TDM) under three different dosing regimens and to optimise vancomycin therapy.

Methods Vancomycin TDM concentrations were noted and compared prospectively in three hospitals. Population pharmacokinetic analysis was performed to optimise dosing using NONMEM software. Patient-tailored optimised dosing regimens were evaluated in a prospective study.

Results Two hundred and seven serum vancomycin concentrations from 116 neonates were analysed. Only 48 neonates (41%) had serum vancomycin concentrations within the therapeutic range of 15–25 mg/l using a current dosing regimen. Concentrations ranged from 5.1 to 61.5 mg/l. Loading doses were required to decrease the risk of sub-therapeutic levels during early treatment. An optimised dosing regimen, taking into account birth weight, current weight, postnatal age and serum creatinine, was developed based on a one-compartment pharmacokinetic model. A prospective validation study in 58 neonates demonstrated a higher percentage of neonates (70.7%, n=41) reaching the therapeutic range and early dosage adaptation (6–12 h post-dose) using an optimised dosing regimen.

Conclusions A patient-tailored optimised dosing regimen should be used routinely to individualise vancomycin continuous infusion therapy in neonates.

  • Pharmacology
  • Infectious Diseases
  • Monitoring
  • Pharmacokinetics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.